NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Serina Therapeutics, Inc. SER
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$130,000
▲ 132.1% vs FY2024
EPS · FY25
$-1.91
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-6351.7%
Net margin · FY25
-14755.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 130,000.00
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 14755 cents on every revenue dollar this year.
Per share
USD -1.91
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-6351.7%
Return on equity, FY2025
ROE
Operating margin-18478.5%
Net margin-14755.4%
Return on assets-280.5%
Each USD of equity lost 6352 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−18.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+56.4%
−18.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.0M
total assets, end of FY2025
Total assetsUSD 7.0M
EquityUSD -37,000.00
CashUSD 3.1M
Current ratio1.71×
Equity funds -1% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
·
·
·
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
·
·
−0.0
0.0
·
·
Net income $B
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.91
−1.51
0.73
−9.70
−0.23
−0.29
−0.33
−0.21
−0.21
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−6351.7
·
·
·
·
·
−251.5
−101.9
−90.4
Shares out B
0.01
0.01
0.00
0.00
0.04
0.04
0.04
0.04
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed